HAE - הכנסה תפעולית לפני ניכוי פחת haemonetics.com
Diversification between hospitals and plasma centers protects Haemonetics Corporation (HAE) revenues from industry fluctuations. The trend in gross operating profit before depreciation clearly confirms this trajectory, while the 369.10 metric indicates the status of current liquidity. Global equipment manufacturing plants ensure business stability, while high margins are sustained by the monopoly position of its blood collection systems.
Haemonetics (HAE) - פילוחי מדדים ודוחות פיננסיים
Christopher Simon's bet on high-margin plasmapheresis technologies and cost optimization translates directly into increased operational efficiency for Haemonetics Corporation (HAE). The EBITDA_Co trend reflects the daily net cash flow before depreciation and interest, capturing the actual balance of supply and demand, which allows investors to assess the business's real ability to generate cash while accounting for market volatility risks during rebalancing.
